blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4274824

EP4274824 - HETEROBICYCLIC COMPOUNDS HAVING AN UREA OR ANALOGUE AND THEIR COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  13.10.2023
Database last updated on 19.07.2024
FormerThe international publication has been made
Status updated on  15.07.2022
Formerunknown
Status updated on  08.02.2022
Most recent event   Tooltip05.03.2024Amendment by applicant 
Applicant(s)For all designated states
IFM Due, Inc.
855 Boylston Street
Suite 1103
Boston, MA 02116 / US
[2023/46]
Inventor(s)01 / VENKATRAMAN, Shankar
Lansdale, Pennsylvania 19446 / US
02 / KATZ, Jason
Newton, Massachusetts 02461 / US
03 / ROUSH, William R.
Boston, Massachusetts 02116 / US
04 / SEIDEL, Hans Martin
Concord, Massachusetts 01742 / US
 [2023/46]
Representative(s)D Young & Co LLP
3 Noble Street
London EC2V 7BQ / GB
[N/P]
Former [2023/46]D Young & Co LLP
120 Holborn
London EC1N 2DY / GB
Application number, filing date22701486.707.01.2022
[2023/46]
WO2022US11609
Priority number, dateUS202163135336P08.01.2021         Original published format: US 202163135336 P
[2023/46]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2022150585
Date:14.07.2022
Language:EN
[2022/28]
Type: A1 Application with search report 
No.:EP4274824
Date:15.11.2023
Language:EN
The application published by WIPO in one of the EPO official languages on 14.07.2022 takes the place of the publication of the European patent application.
[2023/46]
Search report(s)International search report - published on:EP14.07.2022
ClassificationIPC:C07D401/04, C07D401/14, C07D403/04, C07D403/14, A61K31/4155, A61K31/4439, A61K31/444, A61K31/497, A61P35/00
[2023/46]
CPC:
C07D403/04 (EP); C07D403/14 (EP,US); A61P35/00 (EP);
C07D209/40 (US); C07D401/04 (EP); C07D401/14 (EP,US);
C07D403/10 (US); C07D405/14 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2023/46]
Extension statesBA04.08.2023
ME04.08.2023
Validation statesKH04.08.2023
MA04.08.2023
MD04.08.2023
TN04.08.2023
TitleGerman:HETEROBICYCLISCHE VERBINDUNGEN MIT EINEM HARNSTOFF ODER EINEM ANALOG UND IHRE ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON ERKRANKUNGEN IM ZUSAMMENHANG MIT STING-AKTIVITÄT[2023/46]
English:HETEROBICYCLIC COMPOUNDS HAVING AN UREA OR ANALOGUE AND THEIR COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY[2023/46]
French:COMPOSÉS HÉTÉROBICYCLIQUES AYANT UNE URÉE OU UN ANALOGUE ET LEURS COMPOSITIONS POUR LE TRAITEMENT D'ÉTATS ASSOCIÉS À UNE ACTIVITÉ DE STING[2023/46]
Entry into regional phase04.08.2023National basic fee paid 
04.08.2023Designation fee(s) paid 
04.08.2023Examination fee paid 
Examination procedure04.08.2023Examination requested  [2023/46]
04.08.2023Date on which the examining division has become responsible
04.03.2024Amendment by applicant (claims and/or description)
Fees paidRenewal fee
27.12.2023Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[X]WO2008154241  (ABBOTT LAB [US], et al) [X] 1-3,5-9,11,13-17,39 * N- [5 -( 1 -benzyl-5 -cyclopropyl- IH-1 ,2,3 -triazol-4-yl)- 1 H-indazol-3 -yl]-N'-ethylurea; N-benzyl-N'-[5 -( 1 -benzyl-5 -cyclopropyl- 1 H- 1 ,2,3 -triazol-4-yl)- 1 H-indazol-3 -yl]urea; N- [5.( l -benzyl- 1 H- 1 ,2,3 -triazol-4-yl)- 1 H-indazol-3 -yl]-N'-propylurea; N-[5-(l-benzyl-lH-l,2,3-triazol-4-yl)-lH-indazol-3-yl]-N'-ethylurea;; pages 13-27; examples 260, 319, 322 *;
 [X]WO2008156757  (TAKEDA PHARMACEUTICAL [JP], et al) [X] 1,2,4,5,7,11 * Reference example 43 *;
 [X]WO2009112275  (BAYER CROPSCIENCE AG [DE], et al) [X] 1,5-8,11,13-17 * compounds 4-47, 4-60 *;
 [X]WO2011133882  (CYTOKINETICS INC [US], et al) [X] 1-3,9,11,13,14,36 * Page 188 1st compound Page 221 2nd compound *;
 [X]WO2017189663  (ENANTA PHARM INC [US]) [X] 1,4,7,12,14,36 * compounds 345-350, 354, 368-373 *;
 [Y]WO2020010155  (IFM DUE INC [US]) [Y] 1-39 * claims 1-15, 19-114, 116-170 *;
 [Y]WO2020150417  (IFM DUE INC [US]) [Y] 1-39* claims 1-26, 30-127, 136-278 *
by applicantUS7927613
 US2012202848
 WO2015061294
    - LAMMERS et al., "Effect of Intratumoral Injection on the Biodistribution and the Therapeutic Potential of HPMA Copolymer-Based Drug Delivery Systems", Neoplasia, (20060000), vol. 10, pages 788 - 795
    - FILIPSKI, K.J. et al., Current Topics in Medicinal Chemistry, (20130000), vol. 13, pages 776 - 802
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.